CL2012003643A1 - Compuesto analogo del glucagon; composicion que comprende dicho compuesto; uso del compuesto para tratar y/o prevencion de obesidad, dislipidemia o hipertension. - Google Patents

Compuesto analogo del glucagon; composicion que comprende dicho compuesto; uso del compuesto para tratar y/o prevencion de obesidad, dislipidemia o hipertension.

Info

Publication number: CL2012003643A1
Authority: CL; Chile
Prior art keywords: compound; dyslipidemia; glucagon; hypertension; treat
Prior art date: 2010-06-23

Application number

CL2012003643A

Other languages

English (en)

Inventor

Marie Skovgaard

Ditte Riber

Eddi Meier

Jens Rosengren Daugaard

Original Assignee

Zealand Pharma As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-06-23

Filing date

2012-12-21

Publication date

2013-08-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44630045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012003643(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-12-21 Application filed by Zealand Pharma As filed Critical Zealand Pharma As

2013-08-02 Publication of CL2012003643A1 publication Critical patent/CL2012003643A1/es

Links

150000001875 compounds Chemical class 0.000 title 3
208000032928 Dyslipidaemia Diseases 0.000 title 1
102000051325 Glucagon Human genes 0.000 title 1
108060003199 Glucagon Proteins 0.000 title 1
206010020772 Hypertension Diseases 0.000 title 1
208000017170 Lipid metabolism disease Diseases 0.000 title 1
208000008589 Obesity Diseases 0.000 title 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1
229960004666 glucagon Drugs 0.000 title 1
235000020824 obesity Nutrition 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Toxicology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Immunology (AREA)
Obesity (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CL2012003643A 2010-06-23 2012-12-21 Compuesto analogo del glucagon; composicion que comprende dicho compuesto; uso del compuesto para tratar y/o prevencion de obesidad, dislipidemia o hipertension. CL2012003643A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DKPA201000550		2010-06-23
US35862310P	2010-06-25	2010-06-25

Publications (1)

Publication Number	Publication Date
CL2012003643A1 true CL2012003643A1 (es)	2013-08-02

Family

ID=44630045

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2012003643A CL2012003643A1 (es)	2010-06-23	2012-12-21	Compuesto analogo del glucagon; composicion que comprende dicho compuesto; uso del compuesto para tratar y/o prevencion de obesidad, dislipidemia o hipertension.

Country Status (23)

Country	Link
US (2)	US9403894B2 (es)
EP (1)	EP2585481B1 (es)
JP (1)	JP5937582B2 (es)
KR (1)	KR20130086339A (es)
CN (1)	CN103038250A (es)
AP (1)	AP3286A (es)
AR (1)	AR081975A1 (es)
AU (1)	AU2011269427A1 (es)
BR (1)	BR112012033227A2 (es)
CA (1)	CA2802889A1 (es)
CL (1)	CL2012003643A1 (es)
CO (1)	CO6660484A2 (es)
EA (1)	EA201291233A1 (es)
EC (1)	ECSP12012351A (es)
MX (1)	MX2012014774A (es)
NZ (1)	NZ604033A (es)
PE (1)	PE20130326A1 (es)
PH (1)	PH12012502461A1 (es)
SG (1)	SG186276A1 (es)
TN (1)	TN2012000567A1 (es)
TW (1)	TW201202265A (es)
UY (1)	UY33462A (es)
WO (1)	WO2011160630A2 (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2295451A1 (en)	2005-05-04	2011-03-16	Zealand Pharma A/S	Glucagon-like-peptide (GLP-2) analogues
CN101573376B (zh)	2006-11-08	2013-11-06	西兰制药公司	选择性胰高血糖素样肽-2（glp-2）类似物
JP5635532B2 (ja)	2008-12-15	2014-12-03	ジーランドファーマアクティーゼルスカブ	グルカゴン類似体
DK2370460T3 (da)	2008-12-15	2014-08-04	Zealand Pharma As	Glucagon analoger
ES2439499T3 (es)	2008-12-15	2014-01-23	Zealand Pharma A/S	Análogos de glucagón
JP5635529B2 (ja)	2008-12-15	2014-12-03	ジーランドファーマアクティーゼルスカブ	グルカゴン類似体
KR101809024B1 (ko)	2009-07-13	2017-12-14	질랜드 파마 에이/에스	아실화 글루카곤 유사체
UY33462A (es)	2010-06-23	2012-01-31	Zealand Pharma As	Analogos de glucagon
BR112012033225A2 (pt)	2010-06-24	2017-06-20	Zealand Pharma As	análogos do glucagon
SG192038A1 (en) *	2011-01-20	2013-08-30	Zealand Pharma As	Combination of acylated glucagon analogues with insulin analogues
CN104093735B (zh)	2011-09-23	2018-07-06	诺沃—诺迪斯克有限公司	新的胰高血糖素类似物
IN2014CN04401A (es) *	2011-12-23	2015-09-04	Zealand Pharma As
CA2872315A1 (en) *	2012-05-03	2013-11-07	Zealand Pharma A/S	Glucagon-like-peptide-2 (glp-2) analogues
AU2013255751B2 (en)	2012-05-03	2017-10-05	Zealand Pharma A/S	GIP-GLP-1 dual agonist compounds and methods
AR091422A1 (es)	2012-06-14	2015-02-04	Sanofi Sa	Analogos peptidicos de la exendina 4
CN109456400A (zh)	2012-07-23	2019-03-12	西兰制药公司	胰高血糖素类似物
TWI608013B (zh) *	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
EP2895506A1 (en)	2012-09-17	2015-07-22	Imperial Innovations Limited	Peptide analogues of glucagon and glp1
GB2505941A (en) *	2012-09-17	2014-03-19	Imp Innovations Ltd	Peptide analogues of glucagon for the treatment of obesity and diabetes
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HRP20181300T1 (hr)	2012-12-21	2018-10-05	Sanofi	Derivati eksendina-4 kao dvostruki glp1/gip- ili trostruki glp1/gip/glukagon agonisti
EP2976325B1 (en)	2013-03-21	2017-03-01	Sanofi-Aventis Deutschland GmbH	Synthesis of cyclic imide containing peptide products
WO2014147124A1 (en)	2013-03-21	2014-09-25	Sanofi-Aventis Deutschland Gmbh	Synthesis of hydantoin containing peptide products
WO2014161835A1 (en)	2013-04-03	2014-10-09	Sanofi	Modified blood glucose regulating proteins with altered pharmacological activity profile and preparation thereof
MY174727A (en)	2013-04-18	2020-05-11	Novo Nordisk As	Stable, protracted glp-1/glucagon receptor co-agonists for medical use
AP2016009212A0 (en)	2013-10-17	2016-05-31	Zealand Pharma As	Acylated glucagon analogues
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
AU2014345570B2 (en)	2013-11-06	2019-01-24	Zealand Pharma A/S	Glucagon-GLP-1-GIP triple agonist compounds
CA2929459C (en) *	2013-11-06	2022-05-03	Zealand Pharma A/S	Gip-glp-1 dual agonist compounds and methods
WO2015086731A1 (en)	2013-12-13	2015-06-18	Sanofi	Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
WO2015086728A1 (en)	2013-12-13	2015-06-18	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609796A (zh)	2013-12-13	2016-03-16	賽諾菲公司	非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080154B1 (en)	2013-12-13	2018-02-07	Sanofi	Dual glp-1/gip receptor agonists
EP3080149A1 (en)	2013-12-13	2016-10-19	Sanofi	Dual glp-1/glucagon receptor agonists
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
EP3151852A1 (en)	2014-06-04	2017-04-12	Novo Nordisk A/S	Glp-1/glucagon receptor co-agonists for medical use
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
WO2016066744A2 (en)	2014-10-29	2016-05-06	Zealand Pharma A/S	Gip agonist compounds and methods
MA52253A (fr)	2015-02-17	2021-02-17	Lilly Co Eli	Formulation de poudre nasale pour le traitement de l'hypoglycémie
CN107567459B (zh)	2015-03-18	2021-09-24	西兰制药公司	胰淀素类似物
WO2016168388A2 (en)	2015-04-14	2016-10-20	Palatin Technologies, Inc.	Therapies for obesity, diabetes and related indications
KR20170137198A (ko)	2015-04-16	2017-12-12	질랜드 파마 에이/에스	아실화된 글루카곤 유사체
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198628A1 (en)	2015-06-12	2016-12-15	Sanofi	Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
WO2016198624A1 (en)	2015-06-12	2016-12-15	Sanofi	Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
AR105284A1 (es)	2015-07-10	2017-09-20	Sanofi Sa	Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
GB2566228A (en)	2016-06-09	2019-03-06	AmideBio LLC	Glucagon analogs and methods of use thereof
US9994591B2 (en)	2016-08-05	2018-06-12	Boehringer Ingelheim International Gmbh	Oxadiazolopyridine derivates for use as ghrelin O-acyl transferase (GOAT) inhibitors
TWI784968B (zh)	2016-09-09	2022-12-01	丹麥商西蘭製藥公司	澱粉素類似物
KR101887577B1 (ko) *	2016-10-19	2018-09-10	(주)케어젠	항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
TW201832783A (zh)	2016-12-02	2018-09-16	法商賽諾菲公司	包含ｇｌｐ－１／胰高血糖素雙重激動劑、連接子和透明質酸的接合物
KR102502040B1 (ko)	2016-12-09	2023-02-24	질랜드 파마 에이/에스	아실화 glp-1/glp-2 이중 효능제
TWI791539B (zh)	2017-06-16	2023-02-11	丹麥商西蘭製藥公司	用於投予類升糖素胜肽-2(glp-2)類似物的給藥方案
CN111094331B (zh) *	2017-08-16	2024-03-29	东亚St株式会社	酰化胃泌酸调节素肽类似物
JP7083397B2 (ja)	2018-02-02	2022-06-10	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	グレリンｏ－アシルトランスフェラーゼ（ｇｏａｔ）阻害剤として使用するためのトリアゾロピリミジン誘導体
CR20200332A (es)	2018-02-02	2020-09-03	Boehringer Ingelheim Int	Derivados de oxadiazolopiridina sustitidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat)
US11136337B2 (en)	2018-02-02	2021-10-05	Boehringer Ingelheim International Gmbh	Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors
EA202091804A1 (ru)	2018-02-02	2020-12-24	Бёрингер Ингельхайм Интернациональ Гмбх	Гетероциклил-замещенные оксадиазолопиридиновые производные для применения в качестве ингибиторов грелин-о-ацилтрансферазы (goat)
US11028123B2 (en)	2018-04-10	2021-06-08	Sanofi-Aventis Deutschland Gmbh	Capping of unprotected amino groups during peptide synthesis
WO2019197466A1 (en) *	2018-04-10	2019-10-17	Sanofi-Aventis Deutschland Gmbh	Method for cleavage of solid phase-bound peptides from the solid phase
TW202024134A (zh)	2018-12-21	2020-07-01	大陸商江蘇恆瑞醫藥股份有限公司	雙特異性蛋白
TWI771669B (zh)	2019-04-26	2022-07-21	美商美國禮來大藥廠	製備穩定胜肽調配物之方法
CA3147770A1 (en) *	2019-08-13	2021-02-18	Jae Ha Ryu	Exenatide analog and use thereof
CN114641303A (zh)	2019-11-11	2022-06-17	勃林格殷格翰国际有限公司	Npy2受体激动剂
ES2991340T3 (es)	2020-05-22	2024-12-03	Boehringer Ingelheim Int	Procedimiento continuo de fabricación de 7-amino-5-metil-[1,2,5]oxadiazolo[3,4-b]piridín-carboxilato de alquilo
DK4153599T3 (da)	2020-05-22	2024-06-17	Boehringer Ingelheim Int	Fremgangsmåde til at fremstille alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridin-carboxylat
CN113278060B (zh) *	2020-05-29	2022-03-25	东莞云璟生物技术有限公司	Glp-1/胰高血糖素双重激动剂融合蛋白
CA3185637A1 (en)	2020-08-07	2022-02-10	Boehringer Ingelheim International Gmbh	Soluble npy2 receptor agonists
WO2024165571A2 (en)	2023-02-06	2024-08-15	E-Therapeutics Plc	Inhibitors of expression and/or function
WO2025125576A2 (en)	2023-12-15	2025-06-19	E-Therapeutics Plc	Inhibitors of expression and/or function
WO2025133348A1 (en)	2023-12-22	2025-06-26	E-Therapeutics Plc	Inhibitors of expression and/or function
WO2025196502A1 (en)	2024-03-20	2025-09-25	North Carolina Agricultural & Technical State University	Choline kinase inhibitors as a therapeutic treatment for obesity

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ202757A (en)	1981-12-23	1985-11-08	Novo Industri As	Peptides and medicaments
CZ300837B6 (cs)	1996-08-30	2009-08-26	Novo Nordisk A/S	Deriváty GLP-1(7-37) nebo jeho analogy, farmaceutický prostredek je obsahující a jejich použití
NZ334595A (en)	1996-09-09	2000-08-25	Zealand Pharmaceuticals As	Peptide prodrugs containing an alpha-hydroxyacid linker that have increased stability against enzymatic cleavage
DK0929567T3 (da)	1996-09-09	2005-06-27	Zealand Pharma As	Forbedret fastfase-peptidsyntese og middel til anvendelse af en sådan syntese
NZ504258A (en)	1997-11-14	2002-12-20	Amylin Pharmaceuticals Inc	Exendin 3 and 4 agonist compounds for the treatment of diabetes
CA2321026A1 (en)	1998-03-09	1999-09-16	Zealand Pharmaceuticals A/S	Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
RU2214418C2 (ru)	1998-12-07	2003-10-20	Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик Сас	Аналоги glp-1
US6451987B1 (en)	1999-03-15	2002-09-17	Novo Nordisk A/S	Ion exchange chromatography of proteins and peptides
PL351326A1 (en)	1999-03-17	2003-04-07	Novo Nordisk As	Method for acylating peptides and novel acylating agents
EP1076066A1 (en)	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides for lowering blood glucose levels
GB0121709D0 (en)	2001-09-07	2001-10-31	Imp College Innovations Ltd	Food inhibition agent
WO2003053460A1 (en)	2001-12-19	2003-07-03	Eli Lilly And Company	Crystalline compositions for controlling blood glucose
CZ2004710A3 (cs)	2001-12-20	2005-02-16	Eli Lilly And Company	Inzulínová sloučenina s protrahovaným účinkem
GB0300571D0 (en)	2003-01-10	2003-02-12	Imp College Innovations Ltd	Modification of feeding behaviour
BRPI0409600A (pt)	2003-04-29	2006-04-18	Lilly Co Eli	análogo de insulina, composição, método de tratamento de hiperglicemia, e, análogo de pró-insulina
SI1891105T1 (sl)	2005-06-13	2012-07-31	Imp Innovations Ltd	Analogi oksintomodulina in njihovi učinki na prehranjevalno vedenje
WO2007024899A2 (en)	2005-08-23	2007-03-01	The General Hospital Corporation	Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
CN101534846B (zh)	2005-11-07	2014-11-05	印第安纳大学研究及科技有限公司	显示生理学溶解性和稳定性的胰高血糖素类似物
US8343914B2 (en)	2006-01-06	2013-01-01	Case Western Reserve University	Fibrillation resistant proteins
US7928058B2 (en)	2006-02-22	2011-04-19	Merck Sharp & Dohme Corp.	Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the composition
EA020324B1 (ru)	2006-07-18	2014-10-30	Санофи-Авентис	АНТИТЕЛА К РЕЦЕПТОРУ ЭФРИНА EphA2 И ИХ ПРИМЕНЕНИЕ
ES2554773T3 (es)	2006-10-04	2015-12-23	Case Western Reserve University	Insulina y análogos de la insulina resistentes a la fibrilación
TWI428346B (zh)	2006-12-13	2014-03-01	Imp Innovations Ltd	新穎化合物及其等對進食行為影響
BRPI0807728A2 (pt)	2007-02-15	2012-04-17	Univ Indiana Res & Tech Corp	co-agonistas de receptor glucagon/glp-1
EP2025684A1 (en)	2007-08-15	2009-02-18	Zealand Pharma A/S	Glucagon analogues
WO2008152403A1 (en) *	2007-06-15	2008-12-18	Zealand Pharma A/S	Glucagon analogues
ES2632504T3 (es)	2007-11-20	2017-09-13	Ambrx, Inc.	Polipéptidos de insulina modificados y sus usos
DE102008003566A1 (de)	2008-01-09	2009-07-16	Sanofi-Aventis Deutschland Gmbh	Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
KR20100111682A (ko)	2008-01-09	2010-10-15	사노피-아벤티스 도이칠란트 게엠베하	극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체
DE102008003568A1 (de)	2008-01-09	2009-07-16	Sanofi-Aventis Deutschland Gmbh	Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
CN101970476B (zh)	2008-01-09	2014-08-27	塞诺菲-安万特德国有限公司	具有超延迟时效特征的胰岛素衍生物
US8993516B2 (en)	2008-04-14	2015-03-31	Case Western Reserve University	Meal-time insulin analogues of enhanced stability
WO2009132129A2 (en)	2008-04-22	2009-10-29	Case Western Reserve University	Isoform-specific insulin analogues
TWI451876B (zh)	2008-06-13	2014-09-11	Lilly Co Eli	聚乙二醇化之離脯胰島素化合物
CN102123723B (zh)	2008-06-17	2016-05-25	印第安纳大学研究及科技有限公司	胰高血糖素/glp-1受体共激动剂
KR20110039230A (ko)	2008-06-17	2011-04-15	인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션	생리학적 ｐＨ 완충액에서 강화된 용해도 및 안정성을 나타내는 글루카곤 유사체
PL219335B1 (pl)	2008-07-04	2015-04-30	Inst Biotechnologii I Antybiotyków	Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
MY158627A (en)	2008-07-31	2016-10-31	Univ Case Western Reserve	Halogen-stabilized insulin
JP5635529B2 (ja) *	2008-12-15	2014-12-03	ジーランドファーマアクティーゼルスカブ	グルカゴン類似体
ES2439499T3 (es)	2008-12-15	2014-01-23	Zealand Pharma A/S	Análogos de glucagón
JP5635532B2 (ja) *	2008-12-15	2014-12-03	ジーランドファーマアクティーゼルスカブ	グルカゴン類似体
DK2370460T3 (da)	2008-12-15	2014-08-04	Zealand Pharma As	Glucagon analoger
EP2376521B1 (en)	2008-12-19	2016-04-13	Indiana University Research and Technology Corporation	Amide-based insulin prodrugs
CA2747490C (en)	2008-12-19	2017-02-14	Indiana University Research And Technology Corporation	Insulin analogs
CN101519446A (zh)	2009-03-31	2009-09-02	上海一就生物医药有限公司	一种重组人胰岛素及其类似物的制备方法
KR101809024B1 (ko)	2009-07-13	2017-12-14	질랜드 파마 에이/에스	아실화 글루카곤 유사체
JP2013517307A (ja)	2010-01-20	2013-05-16	ジーランドファーマアクティーゼルスカブ	心臓病の処置
UY33462A (es)	2010-06-23	2012-01-31	Zealand Pharma As	Analogos de glucagon
BR112012033225A2 (pt)	2010-06-24	2017-06-20	Zealand Pharma As	análogos do glucagon
SG192038A1 (en)	2011-01-20	2013-08-30	Zealand Pharma As	Combination of acylated glucagon analogues with insulin analogues
IN2014CN04401A (es)	2011-12-23	2015-09-04	Zealand Pharma As
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
AP2016009212A0 (en)	2013-10-17	2016-05-31	Zealand Pharma As	Acylated glucagon analogues

2011
- 2011-06-22 UY UY0001033462A patent/UY33462A/es not_active Application Discontinuation
- 2011-06-22 AR ARP110102166A patent/AR081975A1/es unknown
- 2011-06-23 BR BR112012033227A patent/BR112012033227A2/pt not_active IP Right Cessation
- 2011-06-23 EA EA201291233A patent/EA201291233A1/ru unknown
- 2011-06-23 CN CN2011800305150A patent/CN103038250A/zh active Pending
- 2011-06-23 EP EP11741513.3A patent/EP2585481B1/en active Active
- 2011-06-23 KR KR1020137000529A patent/KR20130086339A/ko not_active Withdrawn
- 2011-06-23 AP AP2013006669A patent/AP3286A/xx active
- 2011-06-23 PH PH1/2012/502461A patent/PH12012502461A1/en unknown
- 2011-06-23 TW TW100122081A patent/TW201202265A/zh unknown
- 2011-06-23 NZ NZ604033A patent/NZ604033A/en not_active IP Right Cessation
- 2011-06-23 MX MX2012014774A patent/MX2012014774A/es not_active Application Discontinuation
- 2011-06-23 WO PCT/DK2011/000067 patent/WO2011160630A2/en not_active Ceased
- 2011-06-23 AU AU2011269427A patent/AU2011269427A1/en not_active Abandoned
- 2011-06-23 JP JP2013515697A patent/JP5937582B2/ja not_active Expired - Fee Related
- 2011-06-23 US US13/702,841 patent/US9403894B2/en not_active Expired - Fee Related
- 2011-06-23 SG SG2012090890A patent/SG186276A1/en unknown
- 2011-06-23 CA CA2802889A patent/CA2802889A1/en not_active Abandoned
- 2011-06-23 PE PE2012002434A patent/PE20130326A1/es not_active Application Discontinuation
2012
- 2012-11-30 TN TNP2012000567A patent/TN2012000567A1/en unknown
- 2012-12-20 EC ECSP12012351 patent/ECSP12012351A/es unknown
- 2012-12-21 CL CL2012003643A patent/CL2012003643A1/es unknown
- 2012-12-21 CO CO12232550A patent/CO6660484A2/es unknown
2016
- 2016-06-27 US US15/194,025 patent/US20160304576A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP2585481A2 (en)	2013-05-01
TW201202265A (en)	2012-01-16
CO6660484A2 (es)	2013-04-30
JP5937582B2 (ja)	2016-06-22
EP2585481B1 (en)	2015-08-19
KR20130086339A (ko)	2013-08-01
AR081975A1 (es)	2012-10-31
MX2012014774A (es)	2013-01-29
US20130157935A1 (en)	2013-06-20
BR112012033227A2 (pt)	2017-06-20
AP3286A (en)	2015-05-31
SG186276A1 (en)	2013-01-30
US9403894B2 (en)	2016-08-02
TN2012000567A1 (en)	2014-04-01
JP2013534919A (ja)	2013-09-09
WO2011160630A3 (en)	2012-02-16
AU2011269427A1 (en)	2012-12-20
CA2802889A1 (en)	2011-12-29
NZ604033A (en)	2014-12-24
CN103038250A (zh)	2013-04-10
ECSP12012351A (es)	2013-01-31
AP2013006669A0 (en)	2013-01-31
PH12012502461A1 (en)	2013-02-18
EA201291233A1 (ru)	2013-07-30
WO2011160630A2 (en)	2011-12-29
US20160304576A1 (en)	2016-10-20
PE20130326A1 (es)	2013-03-17
UY33462A (es)	2012-01-31

Publication	Publication Date	Title
CL2012003643A1 (es)	2013-08-02	Compuesto analogo del glucagon; composicion que comprende dicho compuesto; uso del compuesto para tratar y/o prevencion de obesidad, dislipidemia o hipertension.
CL2014002873A1 (es)	2015-04-24	Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2011001299A1 (es)	2012-01-13	Compuestos derivados de benzotiazoles; composicion farmaceutica; y su uso como inhibidores de raf para el tratamiento o profilaxis del cancer.
BR112012004335A2 (pt)	2015-09-08	composto, composição farmacêutica, e, uso do composto.
CL2011002877A1 (es)	2012-05-25	Anticuerpo que reconoce el dominio fnd1 del receptor ax1; composicion farmaceutica que lo comprende; y su uso para tratar cancer.
CL2012003415A1 (es)	2013-08-09	Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
CL2015001207A1 (es)	2015-07-03	Composición para prevenir o tratar diabetes, diabesidad o complicaciones diabéticas, que comprende un análogo de oxintomodulina; y uso de la composición.
CL2014000801A1 (es)	2014-09-12	Variante de factor 21 de crecimiento de fibroblasto humano (fgf21); composicion farmaceutica que lo comprende; y su uso para tratar diabetes tipo 2, obesidad, dislipidemia, sindrome metabolico o cualquier combinacion de los mismos.
CL2013001338A1 (es)	2014-03-28	Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
CL2012002606A1 (es)	2013-10-18	Composicion farmaceutica que comprende (-)-carvona, (+)-carvona, trans-geraniol y al menos un componente elegido de aceites esenciales para uso en el tratamiento y prevencion de enfermedades virales.
CL2013003372A1 (es)	2014-07-25	Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
BR112014031262A2 (pt)	2017-06-27	composições biocatalisadoras inovadoras e processos para uso.
CL2012000772A1 (es)	2012-08-24	Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata.
CL2013000801A1 (es)	2013-11-29	Composicion farmaceutica que comprende un inhibidor de rankl y una hormona o un derivado de la misma, y uso del inhibidor rankl para preparar dicha composicion
GT201400147A (es)	2015-04-06	Pirimidinas y triazinas fusionadas sustituidas y su uso
BR112012016398A2 (pt)	2018-08-21	Composto imidazopiridinil-aminopiridino substituído, composição farmacêutica que compreende o referido composto e uso do mesmo para o tratamento de uma doença celular proliferativa
CO6440531A2 (es)	2012-05-15	2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
CL2008000793A1 (es)	2008-05-30	Compuestos derivados de dihidroindazol; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno del hierro.
CL2014002348A1 (es)	2015-01-23	Compuestos derivados de fenicol; composicion farmaceutica que los comprende; y su uso para controlar o tratar infecciones bacterianas en ganado.
CL2014003339A1 (es)	2015-04-10	Anticuerpo humanizado anti-trka con propiedades inhibitorias mejoradas; composición que lo comprende; y uso para tratar el dolor.
CL2014003525A1 (es)	2015-04-10	Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension.
CL2012003322A1 (es)	2014-03-28	Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.
CL2015001202A1 (es)	2015-07-03	Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
CL2013001324A1 (es)	2014-05-16	Kit que comprende ec145 y uno o mas agentes quimioterapéuticos adicionales; uso para tratar un cancer.
CL2014001861A1 (es)	2014-11-07	Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia.